Brief: Herantis Pharma Updates On New Biomarker Program

Herantis Pharma Oyj

26/10/2021 06:29

Oct 26 (Reuters) - Herantis Pharma Oyj  HRTIS.HE :
    * HERANTIS PHARMA PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND INFORMATION ABOUT NEW
BIOMARKER
PROGRAM
    * IN NEAR-TO-MID-TERM, WE WILL FOCUS ON IDENTIFYING AND SELECTING KEY BIOMARKERS FOR
CONTINUED
DEVELOPMENT OF RHCDNF AND HER-096
    * RESULTS FROM AN ANIMAL MODEL OF PARKINSON'S DISEASE SHOWING THERAPEUTIC EFFECTS WITH UP TO
ALMOST 70% IMPROVED NEURONAL SURVIVAL

Source text for Eikon:  ID:nWkr73KLjD 
Further company coverage:  HRTIS.HE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))